Target intelligence / Profile preview

Tripartite motif-containing protein 60 (TRIM60)

Target
TRIM60
Molecular classification
E3 SUMO-protein ligase, RING finger protein, Tripartite motif (TRIM) family
01

Overview

Tripartite motif-containing protein 60 (TRIM60) is an E3 SUMO-protein ligase belonging to the TRIM family, notable for containing a RING finger domain involved in protein-protein and protein-DNA interactions. TRIM60 mediates SUMOylation of TAB2, resulting in the suppression of the TRAF6/TAB2/TAK1 complex and inhibition of MAPK and NF-κB signaling pathways, thereby acting as a negative regulator of proinflammatory cytokine production in macrophages and other immune cells. TRIM60 plays a critical role in the innate immune response, with deficiency leading to heightened cytokine production, increased susceptibility to septic shock, and altered responses to bacterial infection. The protein is also characterized by additional TRIM family domains, including B-box, coiled-coil, and PRY-SPRY regions involved in oligomerization and substrate selectivity. Currently, TRIM60 is not the direct target of approved drugs, but its regulatory function in immunity suggests potential relevance for future therapeutic research.

Other names
TRIM60RNF129RNF33FLJ35882RING finger protein 129RING finger protein 33
02

Mechanism of action

Not applicable (no known drugs)

03

Biological functions

Regulation of innate immune responseNegative regulation of MAPK and NF-κB signaling pathwaysMediates SUMOylation of target proteins (e.g., TAB2)Suppresses proinflammatory cytokine productionPost-translational protein modification (SUMOylation)
04

Disease associations

Inflammation (modulates response to infection and septic shock)Infection (resistance to Listeria monocytogenes, susceptibility to sepsis)Other (potential involvement in immune-related diseases due to regulation of cytokine signaling)
05

Safety considerations

Modulation of TRIM60 could alter immune response, increasing risks such as overwhelming inflammation (septic shock) or inadequate pathogen clearanceNo clinically established therapeutic challenges.
06

Biomarkers

Elevated or reduced TRIM60 expression/activity could serve as a biomarker for immune activation or dysregulation (ex: increased in sepsis or infection models)No clinically validated biomarkers currently listed.

Beyond the preview

Go deeper on Tripartite motif-containing protein 60 (TRIM60).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tripartite motif-containing protein 60 (TRIM60).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call